ORAMED PHARMACEUTICALS INC.ORMPEarnings & Financial Report
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
ORMP Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
$0
Operating Profit
$-5.7M
Net Profit
$10.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$0.25
ORAMED PHARMACEUTICALS INC. Q4 FY2025 Financial Summary
ORAMED PHARMACEUTICALS INC. reported revenue of $0 for Q4 FY2025, with a net profit of $10.0M (up 198.2% YoY) (N/A margin). Cost of goods sold was $0, operating expenses totaled $5.7M.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $10.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
ORAMED PHARMACEUTICALS INC. Annual Revenue by Year
ORAMED PHARMACEUTICALS INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.0M).
ORAMED PHARMACEUTICALS INC. Quarterly Revenue & Net Profit History
ORAMED PHARMACEUTICALS INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $10.0M | N/A |
| Q3 FY2025 | $0 | — | $48.4M | N/A |
| Q2 FY2025 | $0 | — | $13.3M | N/A |
| Q1 FY2025 | $2.0M | — | $-7.6M | -382.1% |
| Q4 FY2023 | $0 | — | $12.9M | N/A |
| Q3 FY2023 | $0 | — | $-3.2M | N/A |
| Q2 FY2023 | $674.0K | +0.0% | $-1.2M | -177.2% |
| Q1 FY2023 | $666.0K | +0.0% | $-3.4M | -509.8% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $666000 | $674000 | $0 | $0 | $2.0M | $0 | $0 | $0 |
| YoY Growth | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $159.8M | $156.3M | $230.9M | $220.6M | $147.5M | $161.7M | $220.5M | $230.9M |
| Liabilities | $8.8M | $4.8M | $81.8M | $56.7M | $6.7M | $7.2M | $17.2M | $31.1M |
| Equity | $151.0M | $151.5M | $149.1M | $163.8M | $140.8M | $154.5M | $203.3M | $199.7M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.5M | $-2.6M | $-694000 | $-1.4M | $-3.5M | $-3.5M | $-1.6M | $-466000 |